SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stryker Corp (SYK) is not a strong buy at the moment based on the provided data. While the company has shown impressive financial growth and has a diversified product portfolio, the technical indicators suggest a bearish trend, and hedge funds are selling the stock. For a beginner investor with a long-term strategy, it may be better to wait for a more favorable entry point or clearer positive momentum.
The MACD histogram is -1.57, below 0, and negatively expanding, indicating bearish momentum. The RSI_6 is at 22.281, suggesting the stock is nearing oversold territory but not yet at a clear buy signal. Moving averages are converging, showing no strong trend. The current price of $364.6775 is below the pivot level of $375.58, with support at $362.943 and resistance at $388.217.
Strong financial performance in Q4 2025, with revenue up 11.42% YoY, net income up 55.49% YoY, and EPS up 56.03% YoY.
Analyst sentiment is generally positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings.
Diversified product portfolio and strong growth potential in the medical technology sector.
Hedge funds are selling the stock, with a 119.77% increase in selling activity over the last quarter.
Technical indicators suggest bearish momentum, with MACD and RSI not signaling a clear buy.
Gross margin dropped slightly to 62.61%, down -0.46% YoY.
No recent news or event-driven catalysts to support immediate buying.
In Q4 2025, Stryker reported revenue of $7.171 billion, up 11.42% YoY. Net income increased to $849 million, up 55.49% YoY, and EPS rose to $2.2, up 56.03% YoY. However, gross margin slightly declined to 62.61%, down -0.46% YoY.
Analyst sentiment is mixed to positive. UBS raised the price target to $400 but maintained a Neutral rating. William Blair initiated coverage with an Outperform rating, citing strong growth potential. Barclays raised the price target to $469 with an Overweight rating, while TD Cowen downgraded the stock to Hold with a $387 price target. Overall, analysts see growth potential but note valuation concerns.
